Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
Status:
Recruiting
Trial end date:
2029-07-01
Target enrollment:
Participant gender:
Summary
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable
pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX
followed by surgery and 4 cycles of adjuvant mFOLFIRINOX (arm 1) or to upfront surgery
followed by 12 cycles of adjuvant mFOLFIRINOX (arm 2).
The primary objective of the trial is to determine whether perioperative mFOLFIRINOX improves
overall survival compared with adjuvant mFOLFIRINOX in patients with resectable pancreatic
cancer.
Phase:
Phase 3
Details
Lead Sponsor:
Erasmus Medical Center
Collaborators:
Dutch Cancer Society Dutch Pancreatic Cancer Group